ROYAL OAK—OncoCell MDx, a company developing new, noninvasive molecular diagnostic assays for cancer and other diseases, announced that Marc Stapley has joined the company’s board of directors.
Stapley is currently the president and CEO of Helix, a San Carlos, Calif.-based consumer genomics company. He is also a member of the board of directors of San Clemente, Calif.-based Glaukos Corp., a glaucoma treatment company.
“Marc brings a wealth of relevant experience as an executive and a board member to our team, including a track record of growing and transforming companies in the genomics and molecular diagnosis space,” said Harry Stylli, founder and chairman of OncoCell. “We look forward to benefiting from his strategic insight and to leveraging his capabilities. The OncoCell transformative immunogenomics platform enables us to leverage the power of immune cells to develop a portfolio of compelling noninvasive molecular diagnostics tests for a range of diseases. Our first test to market will be a novel, noninvasive assay for prostate cancer.”
Stapley previously served as executive vice president at Illumina, a San Diego-based manufacturer of genetic variation technology, where he was responsible for corporate strategy, business development and population genomics. During his seven years at Illumina, Stapley also served as the chief administrative officer, responsible for finance, business development, legal, human resources, IT, facilities and government affairs, and as chief financial officer. Prior to Illumina, he held executive finance positions at Pfizer and other large multinational companies.
“With its innovative technology platform and experienced team, OncoCell has a tremendous opportunity to transform the diagnosis and management of prostate cancer and other disease,” Stapley said. “I look forward to serving as a member of OncoCell’s board of directors and to contributing to the company’s growth and success.”
OncoCell’s diagnostic tests use proprietary technologies created at Harvard Medical School by OncoCell MDx’s co-founder, Amin I. Kassis. The company’s noninvasive blood-based immunogenomic assays are designed to aid physicians to better understand underlying disease pathology in prostate cancer and other oncology and non-oncology indications. For more information visit https://oncocellmdx.com/.